Live Demo:
This is a live DrugChatter demonstration using real AI-generated drug queries and analysis.
Want to see how your drug is represented by AI?
Contact DrugChatter
keytruda
Brand Visibility Tracking
How this brand shows up in AI chatbot answers — presence, position, sentiment, and how it stacks up against competitors.
–
Score / 100
Latest check
Weighted composite of presence, position, sentiment, and recommendation strength across tracked prompts.
Presence
–
Avg. position
–
Lower is betterSentiment
–
Recommendation mix — latest check
How the brand was framed across the latest tracked prompts.
Competitive landscape — latest check
Visibility vs. sentiment. Bubble size reflects rank position (bigger = higher-ranked).
Best known for — latest check
PD-1 inhibitor
Strong outcomes in several PD-L1-defined groups across cancers
A large set of approvals across many solid tumors
PD-1 inhibition and treatment discussions involving PD-L1 TPS
Core Claims — latest check
Keytruda is the brand name for pembrolizumab.
There is not usually a simple generic version, though biosimilars may exist in some markets.
Keytruda and Opdivo have equivalent mechanisms but are not automatically interchangeable.
Pembrolizumab has strong evidence in certain biomarker-defined settings.
True head-to-head comparisons between Keytruda and Opdivo are limited.
Differentiators — latest check
Pembrolizumab has strong evidence for certain biomarker-defined settings, including some PD-L1-based strategies.
The response describes Keytruda as having a large set of approvals across many solid tumors.
The response gives Keytruda dosing intervals of every 3 or 6 weeks, compared with Opdivo's every 2 or 4 weeks.
It is a PD-1 inhibitor, while Tecentriq is a PD-L1 inhibitor.
Its discussions emphasize PD-L1 TPS and sometimes MSI-H/dMMR or TMB.
Competitor comparison — latest check
| Brand | Visibility | Sentiment | Position | Recommended |
|---|
30-day composite trends
Score
Overall composite score, per day.
Visibility vs. sentiment
Two lenses on the same conversations — how much the brand shows up, and how it's spoken about.
Average rank position
Where the brand lands among all brands mentioned, in reading order. Lower is better.
Recent checks
| Date | Score | Visibility | Position | Sentiment |
|---|---|---|---|---|
| Oct 16, 2026 | 56 | 74 | 0 | 53 |
| Oct 17, 2026 | 63 | 74 | 0 | 55 |
| Oct 18, 2026 | 60 | 69 | 0 | 52 |
| Oct 19, 2026 | 63 | 71 | 0 | 55 |
| Oct 20, 2026 | 63 | 67 | 1 | 50 |
| Oct 21, 2026 | 60 | 77 | 0 | 51 |
| Oct 22, 2026 | 53 | 73 | 0 | 53 |
| Oct 23, 2026 | 57 | 67 | 0 | 50 |
| Oct 24, 2026 | 59 | 67 | 1 | 54 |
| Oct 25, 2026 | 58 | 66 | 0 | 59 |
| Oct 26, 2026 | 58 | 68 | 1 | 53 |
| Oct 27, 2026 | 58 | 69 | 0 | 50 |
| Oct 28, 2026 | 61 | 70 | 0 | 54 |
| Oct 29, 2026 | 57 | 70 | 0 | 55 |
| Oct 30, 2026 | 60 | 70 | 0 | 50 |
| Oct 31, 2026 | 57 | 73 | 0 | 56 |
| Nov 1, 2026 | 63 | 57 | 0 | 56 |
| Nov 2, 2026 | 58 | 70 | 0 | 50 |
| Nov 3, 2026 | 63 | 69 | 0 | 56 |
| Nov 4, 2026 | 50 | 66 | 0 | 50 |
| Nov 5, 2026 | 62 | 72 | 0 | 54 |
| Nov 6, 2026 | 57 | 63 | 0 | 52 |
| Nov 7, 2026 | 61 | 69 | 0 | 51 |
| Nov 8, 2026 | 57 | 66 | 0 | 50 |
| Nov 9, 2026 | 59 | 72 | 0 | 50 |
| Nov 10, 2026 | 59 | 69 | 0 | 50 |
| Nov 11, 2026 | 61 | 65 | 0 | 53 |
| Nov 12, 2026 | 59 | 70 | 0 | 52 |
| Nov 13, 2026 | 51 | 62 | 0 | 50 |
| Nov 14, 2026 | 64 | 72 | 0 | 59 |